Healthcare Industry News: otitis media
News Release - February 18, 2008
Arbor Pharmaceuticals, Inc. Announces Agreement with Accentia Biopharmaceuticals, Inc. to Launch Company’s Second Pediatric TreatmentCompanies will co-promote NEOTIC™ to pediatricians and ENTs throughout US
Raleigh, NC,--(HSMN NewsFeed)--February 18, 2008 - Arbor Pharmaceuticals, Inc. announced that the company has entered into a sales and marketing agreement with Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) to launch and promote the company's second prescription product throughout the US. NEOTIC™, Arbor's patented prescription ear medication, will treat the pain and inflammation associated with middle ear infections and will be promoted by Accentia's US-based specialty sales force to pediatricians and ENTs.
This sales and marketing agreement is Arbor Pharmaceuticals' second promotional collaboration with Accentia and marks another important milestone in the company's growth plan. In 2007 Arbor successfully launched its first product - ZINOTIC® - for swimmer's ear and has demonstrated significant sales growth since its introduction.
"Arbor Pharmaceuticals is very pleased to be working with Accentia Biopharmaceuticals to bring NEOTIC™ to the market. Accentia is the ideal partner for Arbor as they are an established specialty pharmaceutical company with a strong orientation toward those physicians who treat the majority of ear infections in the US. We are confident that this collaboration will be beneficial to both companies and will serve to introduce an important new product to pediatricians and ENTs for the millions of children that suffer from acute otitis media," says Jarrett Disbrow, President and Chief Executive Officer of Arbor Pharmaceuticals.
Accentia Biopharmaceuticals also announced the NEOTIC™ collaboration. Accentia Chairman and CEO Frank O'Donnell, Jr., MD noted that "Accentia continues to build its specialty pharmaceuticals sales and marketing division with the addition of NEOTIC™. This is an important agreement for both companies as we both continue to execute on our business plans."
About Arbor Pharmaceuticals
Arbor Pharmaceuticals is a Raleigh, North Carolina based specialty pharmaceutical company focused on the licensing, development, and commercialization of products for pediatricians. Founded in 2006, Arbor actively identifies and licenses unique, patent-protected therapies proven to effectively treat common pediatric illnesses. Arbor Pharmaceuticals collaborates with pharmaceutical development companies and established promotional partners in the pharmaceutical industry to develop and market their products in order to serve the needs of pediatricians throughout the US. To learn more about Arbor Pharmaceuticals, visit www.arborpharma.com or send email inquiries to firstname.lastname@example.org.
About Accentia Biopharmaceuticals
Accentia Biopharmaceuticals, Inc. and its subsidiaries is a vertically integrated biopharmaceutical company focused on the development and commercialization of drug candidates that are in late-stage clinical development and typically are based on active pharmaceutical ingredients that have been previously approved by the FDA for other indications. Usually these drug candidates can access the accelerated 505(b)(2) regulatory approval pathway, which is generally less time-consuming and less expensive than the typical 505(b)(1) pathway that must be used for new chemical entities. For further information, visit the company web site at www.accentia.net.
Source: Arbor Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.